Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Harmony Biosciences Holdings, Inc. Market Cap
The Harmony Biosciences Holdings, Inc. (HRMY) share price is expected to increase by 12.91% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered HRMY. Price targets range from $28 at the low end to $56 at the high end. The current analyst consensus for HRMY is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedHRMY 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Harmony Biosciences Holdings, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HRMY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HRMY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ami Fadia Needham | Buy | $52 | Reiterates | Sep 12, 2024 |
| Ashwani Verma UBS | Buy | $56 | Initiates | Sep 10, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Aug 6, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Jun 25, 2024 |
| Ami Fadia Needham | Buy | $52 | Reiterates | Jun 24, 2024 |
| David Hoang Citigroup | Buy | $48 | Initiates | Jun 21, 2024 |
| Ami Fadia Needham | Buy | $52 | Maintains | May 1, 2024 |
| Ami Fadia Needham | Buy | $50 | Reiterates | Apr 30, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $49 | Reiterates | Apr 12, 2024 |
| Ami Fadia Needham | Buy | $50 | Reiterates | Apr 11, 2024 |
| Ami Fadia Needham | Buy | $50 | Reiterates | Apr 9, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $49 | Reiterates | Mar 28, 2024 |
| Graig Suvannavejh Mizuho | Buy | $40 | Maintains | Feb 27, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $49 | Reiterates | Feb 23, 2024 |
| Ami Fadia Needham | Buy | $50 | Maintains | Feb 23, 2024 |
| Ami Fadia Needham | Buy | $53 | Reiterates | Feb 22, 2024 |
| Graig Suvannavejh Mizuho | Buy | $42 | Maintains | Feb 16, 2024 |
| Corinne Jenkins Goldman Sachs | Sell | $28 | Maintains | Jan 9, 2024 |
| Jason Gerberry B of A Securities | Underperform | $30 | Downgrade | Jan 2, 2024 |
When did it IPO
2020
Staff Count
246
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jeffrey M. Dayno M.D.
Market Cap
$2.22B
In 2023, HRMY generated $582.0M in revenue, which was a increase of 32.93% from the previous year. This can be seen as a signal that HRMY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - UBS has begun coverage on Harmony Biosciences Holdings Inc (HRMY), a biopharmaceutical firm specializing in treatments for rare neurological disorders.
Why It Matters - UBS's coverage initiation indicates potential market interest and credibility for Harmony Biosciences, which could influence stock performance and investor sentiment.
Mon, 26 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks utilizes its Zacks Rank system, focusing on earnings estimates and revisions, while also monitoring value, growth, and momentum trends to identify strong stock picks.
Why It Matters - The Zacks Rank system prioritizes earnings estimates and revisions, providing investors with insights into potential stock performance based on growth and momentum trends.
Mon, 26 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investors are comparing Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN) for value in the Medical - Biomedical and Genetics sector.
Why It Matters - The comparison of Harmony Biosciences and Regeneron highlights potential investment opportunities, guiding value investors in making informed decisions based on current market valuations.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will participate in the Wells Fargo 2024 Healthcare Conference in Boston on September 5, 2024, at 9:30 a.m.
Why It Matters - Management participation in investor conferences can indicate company transparency and engagement, potentially influencing investor confidence and stock performance.
Mon, 19 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Harmony Biosciences reports strong revenue growth from WAKIX and aims to diversify through acquisitions. The company has solid financial health and substantial cash reserves for R&D investment.
Why It Matters - Harmony Biosciences shows strong revenue growth from WAKIX and strategic acquisitions that enhance diversification. Solid financial health and R&D investment suggest long-term growth potential, appealing to investors.
Fri, 16 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Harmony Biosciences (HRMY) shares are rising, supported by positive earnings estimate revisions, suggesting potential continued upward movement.
Why It Matters - Rising earnings estimates for Harmony Biosciences suggest improving financial performance, potentially leading to higher stock prices and increased investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
